Pancreatic Adenocarcinoma trials recruiting in Texas
All Pancreatic Adenocarcinoma trials nationally
17
Recruiting in Texas
16
Cities with sites
Cities in Texas
Houston 12San Antonio 8Dallas 7Austin 2Fort Worth 2Abilene 1Conroe 1Edinburg 1Forth Worth 1Irving 1League City 1Richardson 1
Recruiting trials in Texas
- A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
- A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
- A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
- A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
- Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
- Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
- Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
- ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
- Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
- Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
- Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
- Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma